NASTA Honors TestingXperts for Excellence in Quality Engineering for the ‘Most Innovative Project’ in 2024
MECHANICSBURG, Pa., Dec. 5, 2024 /PRNewswire/ — The North American Software Testing Awards (NASTA), which celebrates excellence and innovation in software testing across North America, honored TestingXperts (Tx) with the Most Innovative Project award, for the year 2024. For a leading global r
The PNC Financial Services Group Announces Fourth Quarter and Full Year Conference Call Details
PITTSBURGH, Dec. 5, 2024 /PRNewswire/ — The PNC Financial Services Group, Inc. (NYSE: PNC) expects to issue financial results for the fourth quarter and full year 2024 at approximately 6:30 a.m. (ET), Thursday, Jan. 16, 2025, as previously announced. PNC Chairman and Chief Executive Officer Wi
Smartkem Signs Multi-Year Agreement with FlexiIC to Develop a New Generation of CMOS for Smart Sensors
New project builds on ongoing collaboration to develop custom circuits using Smartkem’s organic transistor technology MANCHESTER, England, Dec. 5, 2024 /PRNewswire/ — Smartkem (NASDAQ: SMTK), which is seeking to change the world of electronics using its disruptive organic thin-film trans
Business France India Concludes Successful French Tech Days 2024 in Bengaluru, Strengthening India-France Innovation Ties
BENGALURU, India, Dec. 5, 2024 /PRNewswire/ — The French Tech Days India 2024, organized by Business France in collaboration with the Paris region, between the 17 – 21 November 2024, has successfully concluded, marking a significant milestone in strengthening France–India ties in the t
" title="Younger Canadians Relying On “Great Wealth Transfer” To Achieve Financial Goals But Expectations May Not Match Reality: Vanguard Study
TORONTO, Dec. 5, 2024 /CNW/ – A new Vanguard Canada survey revealed that the “great wealth transfer” of $1 trillion from boomer parents to their millennial children, may be a disappointment for many investors. Inflation and escalating living costs are forcing younger investors to
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN, Dec. 5, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanida
Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations
Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster presentations showcasing the potential of bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, U.S. VA
SysAid Welcomes Softchoice as Partner to Deliver AI-Powered ITSM Solutions to Its Customers
TORONTO, Dec. 5, 2024 /PRNewswire/ — SysAid, a leading provider of IT and Enterprise Service Management solutions, is pleased to announce its partnership with Softchoice, a globally recognized technology solutions provider. This collaboration marks an exciting step forward in delivering AI-pow
Hyatt Regency Danang Resort and Spa: Tailored Luxury for Every Generation
DANANG, Vietnam, Dec. 5, 2024 /PRNewswire/ — Few destinations capture the spirit of multigenerational celebrations like Hyatt Regency Danang Resort and Spa. Nestled along Vietnam’s stunning central coastline, this resort harmoniously blends luxury, family-friendly experiences, and festiv
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
— Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – — On-track to initiate dosing in combination portion of the ongoing Phase 1
